The Lancet. Haematology
Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.
Jonas S Heitmann, Yacine Maringer, Susanne Jung, Marcel Wacker, Christopher Hackenbruch, Mark Polster, Maddalena Marconato, Annika Nelde, Jens Bauer, Melissa Zwick, Anna-Sophia Baur, Ariane Lehmann, Christopher Krolla, Geoffroy Andrieux, Natalie Köhler
Published: 202610.1016/S2352-3026(25)00323-0
Abstract
BACKGROUND: Therapeutic T-cell activation to induce tumour-specific immune responses promises sustainable cancer control. However, this treatment is not yet widely used because of the challenges of personalised drug design and a shortage of mutation-…
Preview only. Read the full abstract at the source